Theralase Technologies (TSE:TLT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies Inc. has bolstered its clinical team by hiring two Clinical Research Associates with the goal of advancing its Phase II clinical study aimed at combating bladder cancer. The new team members, Bhavya Bajantri and Sonia Keshwani, will focus on expanding clinical study sites, enrolling patients, and ensuring data accuracy as part of the company’s efforts to commercialize its RuvidarTM treatment in North America and beyond. Theralase is committed to providing a safe and effective solution for patients suffering from this severe disease.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.